Stem Cell-Derived Extracellular Vesicles for Cancer Therapy and Tissue Engineering Applications

Recently, stem cells and their secretomes have attracted great attention in biomedical applications, particularly extracellular vesicles (EVs). EVs are secretomes of cells for cell-to-cell communication. They play a role as intercellular messengers as they carry proteins, nucleic acids, lipids, and therapeutic agents. They have also been utilized as drug-delivery vehicles due to their biocompatibility, low immunogenicity, stability, targetability, and engineerable properties. The therapeutic potential of EVs can be further enhanced by surface engineering and modification using functional molecules such as aptamers, peptides, and antibodies. As a consequence, EVs hold great promise as effective delivery vehicles for enhancing treatment efficacy while avoiding side effects. Among various cell types that secrete EVs, stem cells are ideal sources of EVs because stem cells have unique properties such as self-renewal and regenerative potential for transplantation into damaged tissues that can facilitate their regeneration. However, challenges such as immune rejection and ethical considerations remain significant hurdles. Stem cell-derived EVs have been extensively explored as a cell-free approach that bypasses many challenges associated with cell-based therapy in cancer therapy and tissue regeneration. In this review, we summarize and discuss the current knowledge of various types of stem cells as a source of EVs, their engineering, and applications of EVs, focusing on cancer therapy and tissue engineering.

Automated summary

Stem cells and their secretomes, particularly extracellular vesicles (EVs), have gained significant attention in biomedical applications. EVs act as cell-to-cell messengers, carrying proteins, nucleic acids, and other therapeutic agents. They have been utilized as drug-delivery vehicles due to their biocompatibility and other advantageous properties. Stem cells, with their self-renewal and regenerative potential, are ideal sources of EVs for tissue regeneration. However, challenges such as immune rejection and ethical considerations remain significant obstacles. Stem cell-derived EVs have been extensively explored as a cell-free approach in cancer therapy and tissue engineering.